The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  d’Almeida, Sènan M ^a,b,c   Kauffenstein, Gilles ^d   Roy, Charlotte ^d   Basset, Laetitia ^a,b,c   Papargyris, Loukas ^a,b,c   Henrion, Daniel ^d   Catros, Véronique ^e   Ifrah, Norbert ^a,b,c,f   Descamps, Philippe ^f   Croue, Anne ^f   Jeannin, Pascale ^a,b,c,f   Grégoire, Marc ^b,g   Delneste, Yves ^a,b,c,f   Tabiasco, Julie ^a,b,c  

^a UNIVERSITÉ DE NANTES   (France)

^b LabEx IGO Immuno Graft Onco   (France)

^c Equipe Labellisée Ligue Contre le Cancer   (France)

^d UNIVERSITÉ D'ANGERS   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ D'ANGERS   (France)

Author keywords

adenosine; ATP; CD39; IL 10; IL 27; M CSF; ovarian cancer; tumor associated macrophages

Indexed keywords

CD39 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; ECTONUCLEOTIDASE CD39 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 27; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NEUTROPHIL; OVARY CANCER; RECEPTOR DOWN REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; UPREGULATION;

EID: 84976581003     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1178025     Document Type: Article

References (72)

1. P.Romagnani, F.Annunziato, M.P.Piccinni, E.Maggi, S.Romagnani. Th1/Th2 cells, their associated molecules and role in pathophysiology. Eur Cytokine Netw 2000; 11:510-1; PMID:11203198
2. D.C.Lacey, A.Achuthan, A.J.Fleetwood, H.Dinh, J.Roiniotis, G.M.Scholz, M.W.Chang, S.K.Beckman, A.D.Cook, J.A.Hamilton. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol 2012; 188:5752-65; PMID:22547697; http://dx.doi.org/10.4049/jimmunol.1103426
3. A.Sica, A.Mantovani. Macrophage plasticity and polarization:in vivo veritas. J Clin Invest 2012; 122:787-95; PMID:22378047; http://dx.doi.org/10.1172/JCI59643
4. D.Duluc, M.Corvaisier, S.Blanchard, L.Catala, P.Descamps, E.Gamelin, S.Ponsoda, Y.Delneste, M.Hebbar, P.Jeannin. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 2009; 125:367-73; PMID:19378341; http://dx.doi.org/10.1002/ijc.24401
5. E.D.Foucher, S.Blanchard, L.Preisser, E.Garo, N.Ifrah, P.Guardiola, Y.Delneste, P.Jeannin. IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNgamma. PLoS One 2013; 8:e56045; PMID:23409120; http://dx.doi.org/10.1371/journal.pone.0056045
6. W.Zou Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005; http://dx.doi.org/10.1038/nrc1586
7. A.Sica, P.Larghi, A.Mancino, L.Rubino, C.Porta, M.G.Totaro, M.Rimoldi, S.K.Biswas, P.Allavena, A.Mantovani. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18:349-55; PMID:18467122; http://dx.doi.org/10.1016/j.semcancer.2008.03.004
8. A.Mantovani, P.Allavena, A.Sica. Tumour-associated macrophages as a prototypic type II polarised phagocyte population:role in tumour progression. Eur J Cancer 2004; 40:1660-7; PMID:15251154; http://dx.doi.org/10.1016/j.ejca.2004.03.016
9. G.T.Motz, G.Coukos. Deciphering and reversing tumor immune suppression. Immunity 2013; 39:61-73; PMID:23890064; http://dx.doi.org/10.1016/j.immuni.2013.07.005
10. D.Duluc, Y.Delneste, F.Tan, M.P.Moles, L.Grimaud, J.Lenoir, L.Preisser, I.Anegon, L.Catala, N.Ifrah et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007; 110:4319-30; PMID:17848619; http://dx.doi.org/10.1182/blood-2007-02-072587
11. D.Metcalf Control of granulocytes and macrophages:molecular, cellular, and clinical aspects. Science 1991; 25:529-33; PMID:1948028; http://dx.doi.org/10.1126/science.1948028
12. Y.Ma, S.Adjemian, S.R.Mattarollo, T.Yamazaki, L.Aymeric, H.Yang, J.P.Portela Catani, D.Hannani, H.Duret, K.Steegh et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j.immuni.2013.03.003
13. Y.T.Ma, S.Adjemian, H.Yang, J.P.P.Catani, D.Hannani, I.Martins, M.Michaud, O.Kepp, A.Q.Sukkurwala, E.Vacchelli et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Onco Immunol 2013; 2:e24568; PMID:23894718; http://dx.doi.org/10.4161/onci.24568
14. M.Idzko, D.Ferrari, H.K.Eltzschig. Nucleotide signalling during inflammation. Nature 2014; 509:310-7; PMID:24828189; http://dx.doi.org/10.1038/nature13085
15. M.G.Netea, C.A.Nold-Petry, M.F.Nold, L.A.B.Joosten, B.Opitz, J.H.M.van der Meer, F.L.van de Veerdonk, G.Ferwerda, B.Heinhuis, I.Devesa et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113:2324-35; PMID:19104081; http://dx.doi.org/10.1182/blood-2008-03-146720
16. A.Piccini, S.Carta, S.Tassi, D.Lasiglie, G.Fossati, A.Rubartelli. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci U S A 2008; 105:8067-72; PMID:18523012; http://dx.doi.org/10.1073/pnas.0709684105
17. E.R.Lazarowski, J.I.Sesma, L.Seminario-Vidal, S.M.Kreda. Molecular mechanisms of purine and pyrimidine nucleotide release. Adv Pharmacol 2011; 61:221-61; PMID:21586361; http://dx.doi.org/10.1016/B978-0-12-385526-8.00008-4
18. M.R.Elliott, F.B.Chekeni, P.C.Trampont, E.R.Lazarowski, A.Kadl, S.F.Walk, D.Park, R.I.Woodson, M.Ostankovich, P.Sharma et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461:282-U165; PMID:19741708; http://dx.doi.org/10.1038/nature08296
19. L.Aymeric, L.Apetoh, F.Ghiringhelli, A.Tesniere, I.Martins, G.Kroemer, M.J.Smyth, L.Zitvogel. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70:855-8; PMID:20086177; http://dx.doi.org/10.1158/0008-5472.CAN-09-3566
20. A.Ohta, E.Gorelik, S.J.Prasad, F.Ronchese, D.Lukashev, M.M.K.Wong, X.J.Huang, S.Cladwell, K.B.Liu, P.Smith. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006; Aug 29; 103:13132-7; PMID:16916931; http://dx.doi.org/10.1073/pnas.0605251103
21. A.Ohta, M.Sitkovsky. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414:916-20; PMID:11780065; http://dx.doi.org/10.1038/414916a
22. G.Hasko, D.G.Kuhel, J.F.Chen, M.A.Schwarzschild, E.A.Deitch, J.G.Mabley, A.Marton, C.Szabo. Adenosine inhibits IL-12 and TNF-α production via adenosine A(2a) receptor-dependent and independent mechanisms. Faseb J 2000; 14:2065-74; PMID:11023991; http://dx.doi.org/10.1096/fj.99-0508com
23. G.Hasko, C.Szabo, Z.H.Nemeth, V.Kvetan, S.M.Pastores, E.S.Vizi. Adenosine receptor agonists differentially regulate IL-10, TNF-α and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157:4634-40; PMID:8906843
24. H.K.Eltzschig, J.C.Ibla, G.T.Furuta, M.O.Leonard, K.A.Jacobson, K.Enjyoji, S.C.Robson, S.P.Colgan. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium:role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198:783-96; PMID:12939345; http://dx.doi.org/10.1084/jem.20030891
25. G.Hasko, P.Pacher. Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol 2012; 32:865-9; PMID:22423038; http://dx.doi.org/10.1161/ATVBAHA.111.226852
26. G.Hasko, B.N.Cronstein. Adenosine:an endogenous regulator of innate immunity. Trends Immunol 2004; 25:33-9; PMID:14698282; http://dx.doi.org/10.1016/j.it.2003.11.003
27. G.Hasko, J.Linden, B.Cronstein, P.Pacher. Adenosine receptors:therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7:759-70; PMID:18758473; http://dx.doi.org/10.1038/nrd2638
28. M.V.Sitkovsky, D.Lukashev, S.Apasov, H.Kojima, M.Koshiba, C.Caldwell, A.Ohta, M.Thiel. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22:657-82; PMID:15032592; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104731
29. L.Antonioli, P.Pacher, E.S.Vizi, G.Hasko. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013; 19:355-67; PMID:23601906; http://dx.doi.org/10.1016/j.molmed.2013.03.005
30. R.Resta, Y.Yamashita, L.F.Thompson. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998; 161:95-109; PMID:9553767; http://dx.doi.org/10.1111/j.1600-065X.1998.tb01574.x
31. J.Stagg, M.J.Smyth. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010; 29:5346-58; PMID:20661219; http://dx.doi.org/10.1038/onc.2010.292
32. M.Odashima, G.Bamias, J.Rivera-Nieves, J.Linden, C.C.Nast, C.A.Moskaluk, M.Marini, K.Sugawara, K.Kozaiwa, M.Otaka et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005; 129:26-33; PMID:16012931; http://dx.doi.org/10.1053/j.gastro.2005.05.032
33. M.Odashima, M.Otaka, M.Jin, K.Komatsu, I.Wada, T.Matsuhashi, Y.Horikawa, N.Hatakeyama, J.Oyake, R.Ohba et al. Selective A2A adenosine agonist ATL-146e attenuates acute lethal liver injury in mice. J Gastroenterol 2005; 40:526-9; PMID:15942719; http://dx.doi.org/10.1007/s00535-005-1609-9
34. S.Huang, S.Apasov, M.Koshiba, M.Sitkovsky. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997; 90:1600-10; PMID:9269779
35. C.Cekic, Y.J.Day, D.Sag, J.Linden. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 2014; 74:7250-9; PMID:25377469; http://dx.doi.org/10.1158/0008-5472.CAN-13-3583
36. M.V.Sitkovsky, J.Kjaergaard, D.Lukashev, A.Ohta. Hypoxia-adenosinergic immunosuppression:tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008; Oct 1:5947; PMID:18829471; http://dx.doi.org/10.1158/1078-0432.CCR-08-0229
37. J.Stagg, U.Divisekera, N.McLaughlin, J.Sharkey, S.Pommey, D.Denoyer, K.M.Dwyer, M.J.Smyth. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 2010; 107:1547-52; PMID:20080644; http://dx.doi.org/10.1073/pnas.0908801107
38. J.Bastid, A.Cottalorda-Regairaz, G.Alberici, N.Bonnefoy, J.F.Eliaou, A.Bensussan. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2013; 32:1743-51; PMID:22751118; http://dx.doi.org/10.1038/onc.2012.269
39. S.F.Hausler, I.M.Del Barrio, J.Diessner, R.G.Stein, J.Strohschein, A.Honig, J.Dietl, J.Wischhusen. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res 2014; 6:129-39; PMID:24489992
40. A.Young, D.Mittal, J.Stagg, M.J.Smyth. Targeting cancer-derived adenosine:new therapeutic approaches. Cancer Discov 2014; 4:879; PMID:25035124; http://dx.doi.org/10.1158/2159-8290.CD-14-0341
41. P.A.Beavis, N.Milenkovsky, M.HendersonMa, L.B.John, B.Allard, S.Loi, M.H.Kershaw, J.Stagg, P.K.Darcy. Adenosine receptor 2A blockade increase the eficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 2015; 3:506; PMID:25672397; http://dx.doi.org/10.1158/2326-6066.CIR-14-0211
42. B.Allard, S.Pommey, M.J.Smyth, J.Stagg. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 2013; 19:5626; PMID:23983257; http://dx.doi.org/10.1158/1078-0432.CCR-13-0545
43. J.Bastid, A.Regairaz, N.Bonnefoy, C.Dejou, J.Giustiniani, C.Laheurte, S.Cochaud, E.Laprevotte, E.Funck-Brentano, P.Hemon et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 2015; 3:254-65; PMID:25403716; http://dx.doi.org/10.1158/2326-6066.CIR-14-0018
44. B.Zhang, B.Cheng, F.Li, J.Ding, Y.Feng, G.Zhuo, H.Wei, K.Zhao. High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma. Tumor Biol 2015; 36:9411-9; PMID:26113408; http://dx.doi.org/10.1007/s13277-015-3683-9
45. X.Sun, Y.Wu, W.Gao, K.Enjyoji, E.Csizmadia, C.E.Muller, T.Murakami, S.C.Robson. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterol 2010; 139:1030-40; PMID:20546740; http://dx.doi.org/10.1053/j.gastro.2010.05.007
46. S.Deaglio, K.M.Dwyer, W.Gao, D.Friedman, A.Usheva, A.Erat, J.F.Chen, K.Enjyoji, J.Linden, M.Oukka et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65; PMID:17502665; http://dx.doi.org/10.1084/jem.20062512
47. R.F.Zanin, E.Braganhol, L.S.Bergamin, L.F.Campesato, A.Z.Filho, J.C.Moreira, F.B.Morrone, J.Sevigny, M.R.Schetinger, A.T.de Souza Wyse et al. Differential macrophage activation alters the expression profile of NTPDase and ecto-5′-nucleotidase. PLoS One 2012; 7:e31205; PMID:22348056; http://dx.doi.org/10.1371/journal.pone.0031205
48. M.Thibaudin, M.Chaix, R.Boidot, F.Vegran, V.Derangere, E.Limagne, H.Berger, S.Ladoire, L.Apetoh, F.Ghiringhelli. Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Onco Immunol 2016; 5:e1055444; PMID:26942062; http://dx.doi.org/10.1080/2162402X.2015.1055444
49. F.Martinon, V.Petrilli, A.Mayor, A.Tardivel, J.Tschopp. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-41; PMID:16407889; http://dx.doi.org/10.1038/nature04516
50. E.D.Foucher, S.Blanchard, L.Preisser, P.Descamps, N.Ifrah, Y.Delneste, P.Jeannin. IL-34- and M-CSF-induced macrophages switch memory T cells into Th17 cells via membrane IL-1alpha. Eur J Immunol 2014; 45(4):1092-102; PMID:25545357; http://dx.doi.org/10.1002/eji.201444606
51. G.Hasko, P.Pacher, E.A.Deitch, E.S.Vizi. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 2007; 113:264-75; PMID:17056121; http://dx.doi.org/10.1016/j.pharmthera.2006.08.003
52. I.D.Mascanfroni, A.Yeste, S.M.Vieira, E.J.Burns, B.Patel, I.Sloma, Y.Wu, L.Mayo, R.Ben-Hamo, S.Efroni et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 2013; 14:1054-63; PMID:23995234; http://dx.doi.org/10.1038/ni.2695
53. D.Sekar, C.Hahn, B.Brune, E.Roberts, A.Weigert. Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity. Eur J Immunol 2012; 42:1585-98; PMID:22678911; http://dx.doi.org/10.1002/eji.201142093
54. H.B.Cohen, K.T.Briggs, J.P.Marino, K.Ravid, S.C.Robson, D.M.Mosser. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood 2013; 122:1935-45; PMID:23908469; http://dx.doi.org/10.1182/blood-2013-04-496216
55. N.Dubois-Colas, L.Petit-Jentreau, L.B.Barreiro, S.Durand, G.Soubigou, C.Lecointe, J.Klibi, K.Rezai, F.Lokiec, J.Y.Coppee et al. Extracellular Adenosine Triphosphate Affects the Response of Human Macrophages Infected With Mycobacterium tuberculosis. J Infect Dis 2014; 210:824-33; PMID:24604822; http://dx.doi.org/10.1093/infdis/jiu135
56. C.A.Dinarello. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50; PMID:19302047; http://dx.doi.org/10.1146/annurev.immunol.021908.132612
57. N.Riteau, L.Baron, B.Villeret, N.Guillou, F.Savigny, B.Ryffel, F.Rassendren, M.Le Bert, A.Gombault, I.Couillin. ATP release and purinergic signaling:a common pathway for particle-mediated inflammasome activation. Cell Death Dis 2012; 3:e403; PMID:23059822; http://dx.doi.org/10.1038/cddis.2012.144
58. S.A.Levesque, F.Kukulski, K.Enjyoji, S.C.Robson, J.Sevigny. NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur J Immunol 2010; 40:1473-85; PMID:20201036; http://dx.doi.org/10.1002/eji.200939741
59. S.F.Hausler, I.Montalban del Barrio, J.Strohschein, P.Anoop Chandran, J.B.Engel, A.Honig, M.Ossadnik, E.Horn, B.Fischer, M.Krockenberger et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 2011; 60:1405-18; PMID:21638125; http://dx.doi.org/10.1007/s00262-011-1040-4
60. R.Noy, J.W.Pollard. Tumor-associated macrophages:from mechanisms to therapy. Immunity 2014; 41:49-61; PMID:25035953; http://dx.doi.org/10.1016/j.immuni.2014.06.010
61. D.Eichin, J.P.Laurila, S.Jalkanen, M.Salmi. CD73 activity is dispensable for the polarization of M2 macrophages. PLoS One 2015; 10:e0134721; PMID:26258883; http://dx.doi.org/10.1371/journal.pone.0134721
62. C.A.Hunter, R.Kastelein. Interleukin-27:balancing protective and pathological immunity. Immunity 2012; 37:960-9; PMID:23244718; http://dx.doi.org/10.1016/j.immuni.2012.11.003
63. L.Apetoh, F.J.Quintana, C.Pot, N.Joller, S.Xiao, D.Kumar, E.J.Burns, D.H.Sherr, H.L.Weiner, V.K.Kuchroo. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010; 11:854-61; PMID:20676095; http://dx.doi.org/10.1038/ni.1912
64. M.Kido, S.Takeuchi, N.Sugiyama, H.Esaki, H.Nakashima, H.Yoshida, M.Furue. T cell-specific overexpression of interleukin-27 receptor α subunit (WSX-1) prevents spontaneous skin inflammation in MRL/lpr mice. Br J Dermatol 2011; 164:1214-20; PMID:21332454; http://dx.doi.org/10.1111/j.1365-2133.2011.10244.x
65. J.Y.Jung, C.M.Robinson. IL-12 and IL-27 regulate the phagolysosomal pathway in mycobacteria-infected human macrophages. Cell Commun Signal 2014; 12:16; PMID:24618498; http://dx.doi.org/10.1186/1478-811X-12-16
66. G.D.Kalliolias, L.B.Ivashkiv. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol 2008; 180:6325-33; http://dx.doi.org/10.4049/jimmunol.180.9.6325
67. Z.Zhang, B.Zhou, Y.Wu, Q.Gao, K.Zhang, Y.Song, L.Zhang, M.Xi. Prognostic value of IL-27 polymorphisms and the susceptibility to epithelial ovarian cancer in a Chinese population. Immuno Genetics 2014; 66:85-92; PMID:24352695; http://dx.doi.org/10.1007/s00251-013-0753-2
68. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, W.J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
69. J.Duraiswamy, G.J.Freeman, G.Coukos. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900-12; PMID:23975756; http://dx.doi.org/10.1158/0008-5472.CAN-13-1550
70. K.Abiko, M.Mandai, J.Hamanishi, Y.Yoshioka, N.Matsumura, T.Baba, K.Yamaguchi, R.Murakami, A.Yamamoto, B.Kharma et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013; 19:1363-74; PMID:23340297; http://dx.doi.org/10.1158/1078-0432.CCR-12-2199
71. C.J.Maine, N.H.Aziz, J.Chatterjee, C.Hayford, N.Brewig, L.Whilding, A.J.George, S.Ghaem-Maghami. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunotherapy 2014; 63:215-24; PMID:24297569; http://dx.doi.org/10.1007/s00262-013-1503-x
72. B.Levitt, R.J.Head, D.P.Westfall. High-pressure liquid chromatographic-fluorometric detection of adenosine and adenine nucleotides:application to endogenous content and electrically induced release of adenyl purines in guinea pig vas deferens. Anal Biochem 1984; 137:93-100; PMID:6731811; http://dx.doi.org/10.1016/0003-2697(84)90352-X